PMID- 27462153
OWN - NLM
STAT- MEDLINE
DCOM- 20170220
LR  - 20181202
IS  - 1178-2013 (Electronic)
IS  - 1176-9114 (Print)
IS  - 1176-9114 (Linking)
VI  - 11
DP  - 2016
TI  - Functionalized milk-protein-coated magnetic nanoparticles for MRI-monitored 
      targeted therapy of pancreatic cancer.
PG  - 3087-99
LID - 10.2147/IJN.S92722 [doi]
AB  - Engineered nanocarriers have emerged as a promising platform for cancer therapy. 
      However, the therapeutic efficacy is limited by low drug loading efficiency, poor 
      passive targeting to tumors, and severe systemic side effects. Herein, we report 
      a new class of nanoconstructs based on milk protein (casein)-coated magnetic iron 
      oxide (CNIO) nanoparticles for targeted and image-guided pancreatic cancer 
      treatment. The tumor-targeting amino-terminal fragment (ATF) of urokinase 
      plasminogen activator and the antitumor drug cisplatin (CDDP) were engineered on 
      this nanoplatform. High drug loading (~25 wt%) and sustained release at 
      physiological conditions were achieved through the exchange and encapsulation 
      strategy. These ATF-CNIO-CDDP nanoparticles demonstrated actively targeted 
      delivery of CDDP to orthotopic pancreatic tumors in mice. The effective 
      accumulation and distribution of ATF-CNIO-CDDP was evidenced by magnetic 
      resonance imaging, based on the T2-weighted contrast resulting from the specific 
      accumulation of ATF-CNIO-CDDP in the tumor. Actively targeted delivery of 
      ATF-CNIO-CDDP led to improved therapeutic efficacy in comparison with free CDDP 
      and nontargeted CNIO-CDDP treatment. Meanwhile, less systemic side effects were 
      observed in the nanocarrier-treated groups than that in the group treated with 
      free CDDP. Hematoxylin and Eosin and Sirius Red staining of tumor sections 
      revealed the possible disruption of stroma during the treatment with 
      ATF-CNIO-CDDP. Overall, our results suggest that ATF-CNIO-CDDP can be an 
      effective theranostic platform for active targeting-enhanced and image-guided 
      cancer treatment while simultaneously reducing the systemic toxicity.
FAU - Huang, Jing
AU  - Huang J
AD  - Department of Radiology and Imaging Sciences; Center for Systems Imaging.
FAU - Qian, Weiping
AU  - Qian W
AD  - Department of Surgery, Emory University School of Medicine, Atlanta, GA, USA.
FAU - Wang, Liya
AU  - Wang L
AD  - Department of Radiology and Imaging Sciences; Center for Systems Imaging.
FAU - Wu, Hui
AU  - Wu H
AD  - Department of Radiology and Imaging Sciences.
FAU - Zhou, Hongyu
AU  - Zhou H
AD  - Department of Surgery, Emory University School of Medicine, Atlanta, GA, USA.
FAU - Wang, Andrew Yongqiang
AU  - Wang AY
AD  - Ocean Nanotech LLC, Springdale, AR, USA.
FAU - Chen, Hongbo
AU  - Chen H
AD  - School of Life and Environmental Sciences, Guilin University of Electronic 
      Technology, Guilin, Guangxi, People's Republic of China.
FAU - Yang, Lily
AU  - Yang L
AD  - Department of Surgery, Emory University School of Medicine, Atlanta, GA, USA.
FAU - Mao, Hui
AU  - Mao H
AD  - Department of Radiology and Imaging Sciences; Center for Systems Imaging.
LA  - eng
GR  - R01 CA154846/CA/NCI NIH HHS/United States
GR  - U01 CA151810/CA/NCI NIH HHS/United States
GR  - U01 CA198913/CA/NCI NIH HHS/United States
PT  - Journal Article
DEP - 20160707
PL  - New Zealand
TA  - Int J Nanomedicine
JT  - International journal of nanomedicine
JID - 101263847
RN  - 0 (Antineoplastic Agents)
RN  - 0 (Drug Carriers)
RN  - 0 (Ferric Compounds)
RN  - 0 (Magnetite Nanoparticles)
RN  - 0 (Milk Proteins)
RN  - 1K09F3G675 (ferric oxide)
RN  - EC 3.4.21.73 (Urokinase-Type Plasminogen Activator)
RN  - Q20Q21Q62J (Cisplatin)
SB  - IM
MH  - Animals
MH  - Antineoplastic Agents/*administration & dosage/chemistry
MH  - Cell Line, Tumor
MH  - Cisplatin/administration & dosage/therapeutic use
MH  - Drug Carriers/administration & dosage/adverse effects
MH  - Female
MH  - Ferric Compounds/chemistry
MH  - Humans
MH  - Magnetic Resonance Imaging/methods
MH  - Magnetite Nanoparticles/*administration & dosage/chemistry
MH  - Mice, Nude
MH  - Milk Proteins/*chemistry
MH  - Pancreatic Neoplasms/*diagnostic imaging/*drug therapy/pathology
MH  - Urokinase-Type Plasminogen Activator/administration & dosage/chemistry
MH  - Xenograft Model Antitumor Assays
PMC - PMC4939990
OTO - NOTNLM
OT  - active targeting
OT  - cisplatin
OT  - drug delivery
OT  - magnetic nanoparticles
OT  - magnetic resonance imaging
OT  - pancreatic cancer
EDAT- 2016/07/28 06:00
MHDA- 2017/05/26 06:00
PMCR- 2016/07/07
CRDT- 2016/07/28 06:00
PHST- 2016/07/28 06:00 [entrez]
PHST- 2016/07/28 06:00 [pubmed]
PHST- 2017/05/26 06:00 [medline]
PHST- 2016/07/07 00:00 [pmc-release]
AID - ijn-11-3087 [pii]
AID - 10.2147/IJN.S92722 [doi]
PST - epublish
SO  - Int J Nanomedicine. 2016 Jul 7;11:3087-99. doi: 10.2147/IJN.S92722. eCollection 
      2016.